Joshua Salsi is the Head of North America at Biocon Biologics, where he leads the company’s commercial operations and strategic initiatives in the U.S. and Canada.
As a healthcare leader, Joshua has spent his 20+ year career building and leading teams focused on improving access, affordability and overall patient utility of pharmaceuticals. He is a seasoned executive with extensive experience in leading biosimilars and oncology businesses in North America.
Currently, as the Head of North America at Biocon Biologics, Joshua oversees a biosimilars business spanning Oncology, Immunology, and Diabetes therapeutic areas. With a strategic focus on P&L management, he successfully transitioned the North American commercial operations from Viatris to Biocon Biologics, building the commercial infrastructure and ensuring a smooth integration.
Previously, he held key leadership positions at Viatris and Mylan, including Head of Biosimilars, North America, and VP, Head of Oncology, U.S. During this tenure, Joshua demonstrated exceptional strategic acumen, successfully launching the first Pegfilgrastim biosimilar in the U.S. and achieving category leadership. As a staunch advocate for the biosimilars industry, he has engaged in policy and advocacy on Capitol Hill, influencing industry decisions.
Joshua held various senior roles at Pfizer, such as Team Lead for Customer Experience and Strategy and Operations Lead, U.S. Oncology. He played a pivotal role in optimizing customer engagement, restructuring organizations for enhanced differentiation, and driving revenue growth through new product launches and strategic planning.
Joshua holds a Master’s in Business Administration and a Bachelor of Science in Biology from Duquesne University in Pittsburgh, Pennsylvania, U.S. He is known for fostering a collaborative, high-performance culture, leveraging analytics to drive business impact, and delivering innovative solutions in competitive marketplaces.
Joshua is on the Executive Leadership Team of Biocon Biologics.
